• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Effie Caldarola
          • John Garvey
          • Father Ed Dougherty, M.M.
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Father Joseph Breighner
          • Father Collin Poston
          • Robyn Barberry
          • Hanael Bianchi
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Books/CDs/Prayer Cards
        • CR Media platforms
        • Electronic Edition
  • Advertising
  • Shop
        • Purchase Photos
        • Books/CDs/Prayer Cards
        • Magazine Subscriptions
        • Archdiocesan Directory
  • CR Radio
  • News Tips
  • Subscribe
Boxes of mifepristone, the first pill given in a medical abortion, are pictured in a Jan. 13, 2023, photo. (OSV News photo/Evelyn Hockstein, Reuters)

Appeals court rules to keep abortion pill on the market but reinstates prior restrictions

April 13, 2023
By Kate Scanlon
OSV News
Filed Under: Feature, News, Respect Life, World News

WASHINGTON (OSV News) — A federal appeals court April 12 froze portions of a federal judge’s ruling suspending the U.S. Food and Drug Administration’s approval of a medication abortion pill, ruling that the drug can remain on the market but under more strict regulations while a challenge to it plays out.

The Justice Department said it would seek emergency relief from the Supreme Court over the appeals court’s ruling.

A three-judge panel of the 5th U.S. Circuit Court of Appeals agreed to temporarily block U.S. District Judge Matthew Kacsmaryk’s ruling, issued on Good Friday, which suspended the FDA’s approval of the drug mifepristone, the first of two drugs used in a medication or chemical abortion.

But in a 2-1 vote, the panel permitted other portions of that ruling to take effect, prohibiting mifepristone’s use after seven weeks of pregnancy and its distribution by mail, regulations that were in place prior to 2016 on a drug originally approved by the agency in 2000.

A box of the RU-486 drug, known generically as mifepristone and by its brand name Mifeprex, is seen in an undated handout photo.(OSV News photo/courtesy Danco Laboratories)

In an April 13 statement, Attorney General Merrick Garland said the Justice Department “strongly disagrees with the Fifth Circuit’s decision in Alliance for Hippocratic Medicine v. FDA to deny in part our request for a stay pending appeal.”

“We will be seeking emergency relief from the Supreme Court to defend the FDA’s scientific judgment and protect Americans’ access to safe and effective reproductive care,” Garland said.

A coalition of pro-life opponents of the drug mifepristone sought for the FDA’s approval of the drug to be revoked, arguing the government violated its own safety standard in approving the drug more than two decades ago.

Pro-life and pro-abortion activists recognized the mixed results of the appeals court ruling, with pro-life activists applauding reinstated restrictions and pro-abortion activists applauding that the drug will remain on shelves for the time being.

Jeanne Mancini, president of the March for Life, said in a statement that “we are pleased that the 5th Circuit Court of Appeals has temporarily reinstated important and commonsense health and safety protections surrounding the use of chemical abortion drugs.”

“The FDA’s elimination of these safeguards shows a reckless disregard for women’s health when it comes to abortion,” Mancini said. “This dangerous drug regimen has been shown to harm women, sometimes fatally, in addition to ending the lives of unborn children.”

NARAL Pro-Choice America President Mini Timmaraju said in a statement that “once again, we see that our court system has been rigged by the far-right to deliver results that are undemocratic and dangerous.”

“We’re relieved that the FDA’s approval of mifepristone stands for now, but by reinstating outdated and unnecessary restrictions, these judges — many of whom were appointed by a twice-impeached now-indicted former president — put tens of millions of people’s health at risk,” Timmaraju argued. “Anti-choice extremists want to ban all abortion, everywhere. They can’t win elections, so they’ve turned to the courts to do their dirty work. As this legal fight goes on, our reproductive freedom champions across the country must work to protect access to medication abortion no matter what happens next in the courts.”

But Katie Daniel, Susan B. Anthony Pro-Life America’s state policy director, said the group is “very encouraged by this landmark win for women and girls.”

“The Court recognized that the abortion pill is dangerous and rolled back Biden’s reckless mail-order abortion scheme,” Daniel said in a statement. “We still believe it never should have been approved in the first place and we look forward to the Supreme Court hearing this case.”

Daniel argued the FDA “has one job: safeguarding the lives and health of Americans.”

“The evidence clearly shows their failure when it comes to the abortion pill,” she said. “First, the FDA inappropriately fast-tracked this dangerous drug for approval without studying its effects in teenage girls. Then under the Obama and Biden administrations, they loosened one safety standard after another — finally approving mail-order abortion drugs and ignoring the critical importance of in-person doctor supervision — and stonewalled those who sought accountability. The rate of abortion pill-related emergency room visits has skyrocketed over 500 percent since it was approved, while the drug manufacturers have made a handsome profit — with investors reaping a 452 percent return on average.”

“The FDA ignored science and placed politics over the safety of women and girls, as well as the lives of countless unborn children,” Daniel argued. “Finally they are beginning to be held accountable.”

Read More Respect Life

Cupich: Embracing ‘integral ethic of solidarity’ key to living the Gospel in polarized times

Apostolate addresses often overlooked grief from pregnancy, infant loss

GOP presidential candidates debate abortion, immigration at Reagan library

‘Heartbeat law’ ruling breathes new life into South Carolina’s pro-life movement

Florida death-row inmate’s lawyers, bishops, advocacy groups urge stay on Oct. 3 execution

English police apologize to woman arrested for silently praying outside abortion facility

Copyright © 2023 OSV News

Print Print

Primary Sidebar

Kate Scanlon

Our Sunday Visitor is a Catholic publisher serving millions of Catholics globally through its publishing and communication services. Kate Scanlon is a national reporter for OSV News covering Washington. Follow her on Twitter @kgscanlon.

View all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • Baltimore’s beloved Brooks Robinson, Catholic convert, dies at 86
  • Archbishop Lori will ordain 14 permanent deacons Sept. 30
  • Frank Bramble, 75, put his business skills to charitable use throughout archdiocese
  • ‘The most equitable path for all victim-survivors’ – Archdiocese of Baltimore files for Chapter 11 reorganization
  • Fire in packed hall turns wedding joy into tragedy in northern Iraq, killing more than 100

| Latest Local News |

‘The most equitable path for all victim-survivors’ – Archdiocese of Baltimore files for Chapter 11 reorganization

Mount Calvary parishioners combines music, farming and family

New chief advancement officer for Archdiocese of Baltimore sees role as support for ministry

| Latest World News |

Sen. Dianne Feinstein, remembered for ‘extraordinary’ legacy and Barrett controversy, dies at 90

New cardinals say building church unity is urgent need

New cardinals bring experience of ‘peripheries’ to universal church

| Catholic Review Radio |

CatholicReview · Catholic Review Radio

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • Sen. Dianne Feinstein, remembered for ‘extraordinary’ legacy and Barrett controversy, dies at 90
  • ‘The most equitable path for all victim-survivors’ – Archdiocese of Baltimore files for Chapter 11 reorganization
  • New cardinals say building church unity is urgent need
  • New cardinals bring experience of ‘peripheries’ to universal church
  • Movie Review: ‘Paw Patrol: The Mighty Movie’
  • Cupich: Embracing ‘integral ethic of solidarity’ key to living the Gospel in polarized times
  • Basilian Sisters given Catholic Extension’s top honor for ‘powerful witness’ amid peril in Ukraine
  • Apostolate addresses often overlooked grief from pregnancy, infant loss
  • Mount Calvary parishioners combines music, farming and family

Search

Membership

Catholic Press Association of the United States and Canada

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2023 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED